MRK ▼ -2.4% - Merck & Co., Inc.
$MRK Sacituzumab Tirumotecan (Sac-TMT) Reduced the Risk of Death by 32% and the Risk of Disease Progression or Death by 41% Compared to Chemotherapy in Certain Patients With Advanced or Recurrent Endometrial Cancer
26-OCT-2026 11:30 AM ET
Share this post
More filings for $MRK
MRK ▼ -1.9% - Merck & Co., Inc.Oct 23, 2026MRK ▼ -0.9% - Merck & Co., Inc.Oct 22, 2026MRK ▼ -0.9% - Merck & Co., Inc.Oct 22, 2026MRK ▼ -2.3% - Merck & Co., Inc.Oct 22, 2026MRK ▼ -0.3% - Merck & Co., Inc.Oct 21, 2026MRK ▼ -0.3% - Merck & Co., Inc.Oct 21, 2026
View full $MRK filing history →💬 Comments
Loading comments…
Leave a comment